Julphar returns to profitability, posts Dh73 million net profit for Q2
Ras Al Khaimah-based pharmaceutical group continues strong revenue growth with 30 per cent increase from previous year
Gulf Pharmaceutical Industries, popularly known as Julphar, on Sunday said it generated Dh221.3 million in sales during the second quarter of 2021, reflecting an increase of 30 per cent from the same quarter last year.
Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, said it has returned to profitability in April-June 2021 quarter for the first time in three years. The positive trajectory has been fuelled by the revenue growth of high margin products and the manufacturing of the Covid-19 vaccine Hayat-Vax, combined with the positive effects of implemented cost saving measures.
The successful re-entry into core markets such as Saudi Arabia, Oman, Bahrain and Kuwait continued in the past quarter. Progress in the divestment of non-core activities as well as a one-time gain from the settlement of past outstanding balances with distributors have also contributed to the company’s return to profitability.
Additionally, the company considerably strengthened its balance sheet position and reduced its liabilities by Dh309 million, driven by the settlement of previous customer obligations, the restructuring of the bank loans and the divestment of non-core activities. The net profit from continuing operations for the period is Dh67.3 million with a positive EBITDA of Dh88.9 million.
“I am pleased to say that we have done exceptionally well during the first half of the year. The recovery of Julphar has been consistent and steady, and it is encouraging to witness the return to profitability which is testament to the management’s unwavering focus on not only recovering our leadership position, but also unlocking new opportunities for growth,” Saqer Humaid Al Qasimi, chairman of the board, Julphar, said.
Dr Essam Mohamed, chief executive officer of Julphar, said: “Our financial performance this quarter confirms the progress of Julphar’s financial turnaround, which we have been working towards as part of our vision to be a leader in pharmaceuticals serving those in need in the Mena region and beyond. In addition to the re-establishment of Julphar in our key markets, we are very proud of our role in manufacturing the Sinopharm Covid-19 vaccine Hayat-Vax, which marks a significant contribution to the health and well-being of people and, on a larger scale, the sustained economic recovery.”
Looking ahead, Julphar remains focused on expanding the sales activities in key markets to increase market share with its existing portfolio. Furthermore, the company will increase its efforts towards filling its product pipeline to accelerate the introduction of its new products (speciality differentiated generics) from its newly fuelled pipeline, which will make a transformational change to the company’s product portfolio.
Ras Al Khaimah-based pharmaceutical group continues strong revenue... READ MORE
The company is optimistic about the remaining half of 2021 supported... READ MORE
Prime Minister Pham Minh Chinh at the online high-level open... READ MORE
The infrastructure programme, called "Gati Shakti", will help boost... READ MORE
More than 7.9 million PCR tests have been conducted across the... READ MORE
A man, who bought a plot of land for Dh1 million from the company,... READ MORE
The Peter Rabbit attraction houses activities based on the hit... READ MORE
The new line-up boasts a range of major upgrades and features,... READ MORE